
|
CELECOXIB
(brand name: Celebrex)
Pharmacological category:
analgesic, antidysmenorrheal, antirheumatic, nonsteroidal anti-inflammatory
|
 |
|
| |
 |
Reviews |
|
Celecoxib |
Hepatology. 2005 Mar;41(3):579-87.
Effects of celecoxib and naproxen on renal function
in nonazotemic patients with cirrhosis and ascites.
Claria J, Kent JD, Lopez-Parra M, Escolar G, Ruiz-Del-Arbol
L, Gines P, Jimenez W, Vucelic B, Arroyo V.
DNA Unit, Hospital Clinic, Institut d'Investigacions Biomediques August
Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Nonselective inhibition of cyclooxygenase (COX) by nonsteroidal anti-inflammatory
drugs frequently induces renal failure in decompensated cirrhosis. Studies
in experimental cirrhosis suggest that selective inhibitors of the inducible
isoform COX-2 do not adversely affect renal function. However, very limited
information is available on the effects of these compounds on renal function
in human cirrhosis. This investigation consists of a double-blind, randomized,
placebo-controlled trial aimed at comparing the effects of the selective
COX-2 inhibitor celecoxib (200 mg every 12 hours for a total of 5 doses)
on platelet and renal function and the renal response to furosemide (40
mg intravenously) with those of naproxen (500 mg every 12 hours for a total
of 5 doses) and placebo in 28 patients with cirrhosis and ascites. A significant
reduction (P < .05) in glomerular filtration rate (113 +/- 27 to 84 +/-
22 mL/min), renal plasma flow (592 +/- 158 to 429 +/- 106 mL/min) and urinary
prostaglandin E(2) excretion (3430 +/- 430 to 2068 +/- 549 pg/min) and suppression
of the diuretic (urine volume: 561 +/- 128 to 414 +/- 107 mL/h) and natriuretic
(urine sodium: 53 +/- 13 to 34 +/- 10 mEq/h) responses to furosemide were
observed in the group of patients treated with naproxen but not in the other
two groups. Naproxen, but not celecoxib or placebo, significantly inhibited
platelet aggregation (72% +/- 8% to 47% +/- 8%, P < .05) and thromboxane
B(2) production (41 +/- 12 to 14 +/- 5 pg/mL, P < .05). In conclusion,
our results indicate that short-term administration of celecoxib does not
impair platelet and renal function and the response to diuretics in decompensated
cirrhosis. Further studies are needed to evaluate the long-term safety of
this drug in cirrhosis.
|
Osteoarthritis Cartilage. 2005 Mar;13(3):206-10.
Celecoxib improves the efficiency of the locomotor mechanism
in patients with knee osteoarthritis. A randomised, placebo, double-blind
and cross-over trial.
Detrembleur C, De Nayer J, van den Hecke A.
Rehabilitation and Physical Medicine Unit, Universite catholique de
Louvain, Brussels, Belgium.
OBJECTIVE: To compare the effect of celecoxib vs placebo treatment on clinical
and gait variables in knee osteoarthritis (OA) patients; focusing on the
efficiency of the locomotor mechanism. METHODS: Study design: A prospective,
randomised, double-blind placebo-controlled trial. Patients: Eight adult
patients with painful OA of the knee. Outcome measures: Clinical assessment
included knee pain assessed by the visual analogue scale, range of knee
motion assessed by goniometer, and locomotor function status assessed by
a Knee Score Scale. Gait was assessed by means of instrumented analysis
including synchronous kinematic, dynamic, electromyographic, and energetic
recordings. Statistical analysis: The effect of treatment on the primary
variable, the efficiency of the locomotor mechanism, and on secondary clinical
and gait variables was assessed by the Hills and Armitage non-parametric
approach. RESULTS: Celecoxib treatment improved the efficiency of the locomotor
mechanism significantly. Among the secondary outcome measures assessed,
celecoxib treatment improved walking cadence and reduced the knee pain significantly.
CONCLUSION: This study shows that celecoxib is effective in improving locomotor
function and pain in patients with knee OA. |
| Am J Orthop 2002 Aug;31(8):445-51
Efficacy of celecoxib versus ibuprofen in the treatment
of acute pain: a multicenter, double-blind, randomized controlled trial
in acute ankle sprain
Ekman EF, Fiechtner JJ, Levy S, Fort JG
Southern Orthopaedic Sports Medicine, Providence Hospital Columbia, South
Carolina, USA
Ankle sprain is a common acute soft-tissue injury that often results in
pain, inflammation, and ecchymosis. In this multicenter, double-blind,
randomized parallel-group study, 445 adult patients received celecoxib
400 mg/day, ibuprofen 2,400 mg/day, or placebo for 10 days. Patients had
experienced grade 1 or 2 ankle sprains within 48 hours and had moderate
to severe ankle pain. Patient's Global Assessment of Ankle Injury responses,
given on days 4 and 8, showed that the celecoxib group improved significantly
more than the placebo group did, with 67% of the celecoxib group versus
55% of the placebo group improving at day 4 (P < .05). Patient's Assessment
of Ankle Pain Visual Analog Scale on Weight Bearing responses, also given
on days 4 and 8, showed that celecoxib was as efficacious in the treatment
of ankle sprain as the maximum therapeutic dosage of ibuprofen and that,
compared with placebo, it reduced pain significantly more (P < .05).
The celecoxib group recovered and returned to function earlier (after
5 days) than did either the placebo group (8 days) or the ibuprofen group
(6 days); the celecoxib-placebo difference was significant. Celecoxib,
a cyclo-oxygenase-2-specific inhibitor with platelet-function-sparing
properties, may be useful as a multimodal adjuvant in the treatment of
ankle sprain. |
| |
 |
Drug information |
|
| GENERIC NAME: celecoxib
BRAND NAME: Celebrex
DRUG CLASS AND MECHANISM: Celecoxib is a nonsteroidal
anti-inflammatory drug (NSAID) that is used to treat arthritis, pain,
menstrual cramps, and colonic polyps. Prostaglandins are chemicals that
are important contributors to the inflammation of arthritis that causes
the pain, fever, swelling and tenderness. Celecoxib blocks the enzyme
that makes prostaglandins (cyclooxygenase 2), resulting in lower concentrations
of prostaglandins. As a consequence, inflammation and its accompanying
pain, fever, swelling and tenderness are reduced. Celecoxib differs from
other NSAIDs in that it causes less inflammation and ulceration of the
stomach and intestine (at least with short-term treatment) and does not
interfere with the clotting of blood. NSAIDs have been found to prevent
the formation and reduce the size of polyps in patients with the genetic
disease, familial adenomatous polyposis (FAP). In FAP, patients develop
large numbers of polyps in their colons, and the polyps invariably become
malignant. The only cure of FAP requires removal of the entire colon.
Celecoxib is approved as an adjunctive (secondary) treatment among patients
with FAP. The cramping and pain during menstrual periods is due to prostaglandins,
and blocking the production of prostaglandins with celecoxib reduces the
cramps and pain.
PREPARATIONS: Capsules: 100 mg (white with a blue band),
200 mg (white with a gold band), 400 mg (white with a green band)
STORAGE: Capsules should be stored at 25°C (77°F).
It is okay for brief periods in temperatures between 15-30°C (59-86°F).
PRESCRIBED FOR: Celecoxib is used for the relief of
pain, fever, swelling, and tenderness caused by osteoarthritis and rheumatoid
arthritis . Celecoxib does not prevent the progression of either type
of arthritis. It reduces only the symptoms and signs of arthritis. Celecoxib
has been approved for patients with familial FAP who have not had their
colons removed. Celebrex also is approved for the relief of acute pain
and the pain of menstrual cramps (primary dysmenorrhea).
DOSING: The lowest effective dose should be used for
each patient. For the management of osteoarthritis, the dose usually is
100 mg twice daily or 200 mg as a single dose. For rheumatoid arthritis,
the dose usually is 100 or 200 mg twice daily. For acute pain or menstrual
cramps, the dose is 400 mg as a single dose on the first day followed
by an additional 200 mg if needed, then 200mg twice daily as needed. For
FAP, the recommended dose is 400 mg twice daily.
DRUG INTERACTIONS: Concomitant use of celecoxib with
aspirin or other NSAIDs (e.g., ibuprofen, naproxen, etc.) may increase
the occurrence of stomach and intestinal ulcers.
Fluconazole (Diflucan) increases the concentration of celecoxib in the
body by inhibiting the breakdown of celecoxib in the liver. Therefore,
treatment with celecoxib should be initiated at the lowest recommended
doses in patients who are taking fluconazole.
Celecoxib increases the concentration of lithium (Eskalith) in the blood
by 17%. Therefore, lithium therapy should be closely monitored during
and after therapy with celecoxib.
Persons taking the anticoagulant (blood thinner) warfarin (Coumadin)
should have their blood tested when initiating or changing celecoxib treatment,
particularly in the first few days, for any changes in the effects of
the anticoagulant.
Persons who drink more than 3 alcoholic beverages per day may be at increased
risk of developing stomach ulcers when taking NSAIDs, and this also may
be true with celecoxib.
PREGNANCY: Celecoxib has not been studied in pregnant
women. In animal studies, doses that were twice the maximally recommended
dose were harmful to the fetus. Celecoxib should only be used in pregnant
women when the benefits outweigh the potential risk to the fetus.
NURSING MOTHERS: The use of celecoxib in nursing mothers
has not been evaluated.
SIDE EFFECTS: Although stomach and intestinal ulcers
occur with the use of celecoxib, their incidence is less than with other
NSAIDs in short-term studies.
Celecoxib does not interfere with the function of the blood platelets
and, as a result, does not reduce clotting and lead to increased bleeding
like other NSAIDs.
The most common adverse effects are headache, abdominal pain, dyspepsia,
diarrhea, nausea, flatulence and insomnia. Other side effects include
fainting, kidney failure, heart failure, aggravation of hypertension,
chest pain, ringing in the ears, deafness, stomach and intestinal ulcers,
bleeding, blurred vision, anxiety, photosensitivity, weight gain, water
retention, flu-like symptoms, drowsiness and weakness.
Allergic reactions can occur with celecoxib. Individuals who have developed
allergic reactions (rash, itching, difficulty breathing) from sulfonamides
(e.g., Bactrim), aspirin or other NSAIDs may experience an allergic reaction
to celecoxib and should not take celecoxib. Glossary content Copyright
© 1996-2002 MedicineNet, Inc. All rights reserved.
Caution! Before starting
to take this medicine, it is vital that you should consult your doctor!
Do not use it on your own initiative, without medical advice.
Also, you should read carefully important health information about this
drug given here:
www.nlm.nih.gov |
| |
 |
Order now ! |
|
|
CELEBREX
Substance: Celecoxib
Manufacturer : Pfizer
|
|
Dosage |
Packing |
Price |
Pay now |
200 mg |
20 tab |
USD 59.00 |
|
200 mg |
60 tab |
USD 169.00 |
|
CELEBREX - GENERIC
Substance: Celecoxib
|
|
Dosage |
Packing |
Price |
Pay now |
100 mg |
100 caps |
USD 65.00 |
|
100 mg |
200 caps |
USD 125.00 |
|
200 mg |
100 caps |
USD 99.00 |
|
200 mg |
200 caps |
USD 212.00 |
|
|
|
| |
| 
|
|